CD68 and breast carcinoma: Clinical specimens of 59 breast cancer patients collected from the hospital also demonstrated that the median survival time in the high CD68+ macrophage infiltration group (1176 days) was lower than that in the low infiltration group (1740 days) (Figure 2C).